26 May, 2014 by The TZ Newswire Staff Comments Off on ‘Abundantly wrong’ to expect correction: Gartman
‘Abundantly wrong’ to expect correction: Gartman
Calls for a market correction have been wrong for years and will likely stay wrong, Dennis Gartman, the Gartman Letter’s publisher, said.
26 May, 2014 by The TZ Newswire Staff Comments Off on GBP/USD picking up, but not enough
GBP/USD picking up, but not enough
FXStreet (Guatemala) – GBP/USD is trading at 1.6868, up 0.16% on the day, having posted a daily…
26 May, 2014 by The TZ Newswire Staff Comments Off on Obama Administration Exposes Kabul CIA Chief Accidentally, Media Shrugs
Obama Administration Exposes Kabul CIA Chief Accidentally, Media Shrugs
Another day, another fumble by the Obama administration (intentional or not). 11 years after former CIA operative Valerie Plame was deliberately exposed by the Bush administration as the US officials tried to apply pressure on her husband, an American diplomat criticizing the US invasion to Iraq; the Obama Administration’s press service unwittingly put the real name of the CIA’s top spy in Afghanistan on the ‘pool report’ distributed to over 6,000 journalists.
26 May, 2014 by The TZ Newswire Staff Comments Off on NZD/USD extends bounce off 0.8525
NZD/USD extends bounce off 0.8525
FXStreet (Bali) – NZD/USD rose in early Tokyo touching a session high of 0.8573, further recovering…
26 May, 2014 by The TZ Newswire Staff Comments Off on USD/JPY outlook improving – UOB Group
USD/JPY outlook improving – UOB Group
FXStreet (Barcelona) – The Market Strategy Team at UOB Group noted the outlook for USD/JPY is…
26 May, 2014 by The TZ Newswire Staff Comments Off on How AstraZeneca escaped Pfizer’s clutches this time
How AstraZeneca escaped Pfizer’s clutches this time
On a sunny day in San Francisco last January, AstraZeneca Chief Executive Pascal Soriot was on his way to the Westin St. Francis hotel on Union Square to give investors some unexpectedly good news. What shareholders did not know at the time was that two days earlier AstraZeneca had written to U.S. rival Pfizer rejecting its offer to buy the London-based group for close to $100 billion. Shares rose on the 2017 sales forecast as investors looked forward to a time when AstraZeneca would finally put behind it a wave of patent expiries on its drugs.